Findings

What do systematic reviews say?

110 questions · 115 findings · 14 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 2.6%GRADE not reported 1 · 0.9%Very low 4 · 3.5%Low 42 · 36.5%Moderate 54 · 47%High 11 · 9.6%

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 239 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 266 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.2 [0.66, 2.17]
2 studies · 227 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension group 2 ‐ 4

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i probably leads to higher improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 11.31 [4.9, 26.14]
2 studies · 146 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension group 2 ‐ 4

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

PASP · people with pulmonary hypertension group 2 ‐ 4

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 146 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension due to CTEPH

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 17.18 [0.78, 380.84]
1 study · 19 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension due to CTEPH

2 findings from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low
Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Mortality ‐ sildenafil versus bosentan · people with pulmonary hypertension due to CTEPH

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in mortality ‐ sildenafil versus bosentan compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.36 [0.22, 8.48]
1 study · 106 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to CTEPH

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

PAP · people with pulmonary hypertension due to CTEPH

2 findings from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low
Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Cardiac index · people with pulmonary hypertension due to CTEPH

2 findings from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low
Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

PVR · people with pulmonary hypertension due to CTEPH

2 findings from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low
Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension due to lung disease

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i may leads to higher improvement in WHO functional class compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 44.33 [4.78, 410.94]
1 study · 40 participants
Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 350 participants
High

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension due to lung disease

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 238 participants
Moderate